Actively Recruiting
Sustained Release Oral Formulation for Treatment of Parkinson's Disease
Led by University of Minnesota · Updated on 2025-07-10
6
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson's disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in normal volunteers.
CONDITIONS
Official Title
Sustained Release Oral Formulation for Treatment of Parkinson's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Normal healthy
- Are 18-65 years of age
- Are not currently taking medications regularly
- Able to fast 6 hours (water allowed)
You will not qualify if you...
- Pregnancy
- Inability to fast
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
Research Team
R
Research Coordinator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here